2-(1-哌啶基)苄胺 | 72752-54-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 2-(1-哌啶基)苄胺
• 中文别名: 2-双哌啶苯甲胺
• 英文名称: (2-(piperidin-1-yl)phenyl)methanamine
• 英文别名: 2-Piperidinobenzylamine；(2-piperidin-1-ylphenyl)methanamine
• CAS: 72752-54-6
• 化学式: C₁₂H₁₈N₂
• mdl: MFCD02682071
• 分子量: 190.288
• InChiKey: VNNYEXSABSADDW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  C
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2933399090

SDS

Name:	2-Piperidinobenzylamine, 90+% Material Safety Data Sheet
Synonym:
CAS:	72752-54-6

Section 1 - Chemical Product MSDS Name: 2-Piperidinobenzylamine, 90+% Material Safety Data Sheet
Synonym:

---

SECTION 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
72752-54-6	2-Piperidinobenzylamine	90+%	unlisted

Hazard Symbols: C
Risk Phrases: 34

---

SECTION 3 - HAZARDS IDENTIFICATION EMERGENCY OVERVIEW Causes burns.Air sensitive. Potential Health Effects
Eye:
Causes eye burns.
Skin:
Causes skin burns.
Ingestion:
Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Not available.

---

SECTION 4 - FIRST AID MEASURES
Eyes:
Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid immediately. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Do not induce vomiting. Get medical aid immediately. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:
Treat symptomatically and supportively.

---

SECTION 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
In case of fire, use water, dry chemical, chemical foam, or alcohol-resistant foam. Use foam, dry chemical, or carbon dioxide.

---

SECTION 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container.

---

SECTION 7 - HANDLING and STORAGE
Handling:
Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Use only in a chemical fume hood.
Storage:
Store in a cool, dry place. Store in a tightly closed container. Corrosives area. Store under an inert atmosphere.

---

SECTION 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low. Use adequate general or local exhaust ventilation to keep airborne concentrations below the permissible exposure limits. Exposure Limits CAS# 72752-54-6: Personal Protective Equipment
Eyes:
Not available.
Skin:
Wear appropriate protective gloves and clothing to prevent skin exposure. Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Wear a NIOSH/MSHA or European Standard EN 149 approved full-facepiece airline respirator in the positive pressure mode with emergency escape provisions. Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

SECTION 9 - PHYSICAL AND CHEMICAL PROPERTIES
Physical State: Viscous liquid
Color: colorless
Odor: sweetish odor
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C12H18N2
Molecular Weight: 190.29

---

SECTION 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials, exposure to air.
Incompatibilities with Other Materials:
Strong oxidizing agents, acids.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide, acrid smoke and fumes.
Hazardous Polymerization: Has not been reported

---

SECTION 11 - TOXICOLOGICAL INFORMATION RTECS#: CAS# 72752-54-6 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2-Piperidinobenzylamine - Not listed by ACGIH, IARC, or NTP.

---

SECTION 12 - ECOLOGICAL INFORMATION

---

SECTION 13 - DISPOSAL CONSIDERATIONS Dispose of in a manner consistent with federal, state, and local regulations.

---

SECTION 14 - TRANSPORT INFORMATION IATA
Shipping Name: AMINES, LIQUID, CORROSIVE, N.O.S.
Hazard Class: 8
UN Number: 2735
Packing Group: III IMO
Shipping Name: AMINES, LIQUID, CORROSIVE, N.O.S.
Hazard Class: 8
UN Number: 2735
Packing Group: III RID/ADR
Shipping Name: AMINES, LIQUID, CORROSIVE, N.O.S.
Hazard Class: 8
UN Number: 2735
Packing group: III

---

SECTION 15 - REGULATORY INFORMATION European/International Regulations European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 34 Causes burns.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S 36/37/39 Wear suitable protective clothing, gloves and eye/face protection. S 45 In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible). WGK (Water Danger/Protection) CAS# 72752-54-6: No information available. Canada None of the chemicals in this product are listed on the DSL/NDSL list. CAS# 72752-54-6 is not listed on Canada's Ingredient Disclosure List. US FEDERAL TSCA CAS# 72752-54-6 is not listed on the TSCA inventory. It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
MSDS Creation Date: 4/03/2003 Revision #0 Date: Original. The information above is believed to be accurate and represents the best information currently available to us. However, we make no warranty of merchantability or any other warranty, express or implied, with respect to such information, and we assume no liability resulting from its use. Users should make their own investigations to determine the suitability of the information for their particular purposes. In no way shall the company be liable for any claims, losses, or damages of any third party or for lost profits or any special, indirect, incidental, consequential or exemplary damages, howsoever arising, even if the company has been advised of the possibility of such damages.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-(1-哌啶基)苄胺 在 盐酸 、 四氯化碳 、 sodium hydroxide 、 sodium sulfate 、 三乙胺 、 三苯基膦 、 lithium diisopropyl amide 作用下， 以 乙醇 、 乙腈 为溶剂， 反应 68.0h， 生成 2-Ethoxy-4-(N-(1-(2-piperidino-phenyl)-4-penten-1-yl)-aminocarbonylmethyl]-benzoic acid
  参考文献：
  名称：

  瑞格列奈和相关的降血糖苯甲酸衍生物。

  摘要：

  研究了两个系列的降血糖苯甲酸衍生物（5、6）的构效关系。当2-甲氧基被亚烷基亚氨基残基取代时，系列5由美格替宁（3）产生。用顺式3、5-二甲基哌啶子基（5h）和八亚甲基亚氨基（5l）残基观察到最大活性。当将2-甲氧基，5-氟和α-甲基残基替换为2-哌啶子基，5-氢和较大的α-烷基残基时，具有反向酰胺基功能的meglitinide类似物4产生6系列， 分别。羧基邻位的烷氧基残基进一步增加了大鼠的活性和作用时间。最具活性的外消旋化合物6al（R4 =异丁基； R =乙氧基）的活性比磺酰脲（SU）格列本脲（1）高12倍。发现活性主要存在于（S）-对映异构体中。与SUs 1和2（格列美脲）相比，活性最高的对映异构体（S）-6al（AG-EE 623 ZW;瑞格列奈; ED50 = 10 micro / kg po）活性高25和18倍。瑞格列奈对2型糖尿病患者是一种有用的治疗药物。FDA和EMEA最

  DOI：

  10.1021/jm9810349
• 作为产物：
  描述：

  2-(1-哌啶基)苯甲腈 在 镍 氨 、 氢气 作用下， 以 甲醇 为溶剂， 50.0 ℃ 、500.0 kPa 条件下， 反应 4.0h， 以100%的产率得到2-(1-哌啶基)苄胺
  参考文献：
  名称：

  瑞格列奈和相关的降血糖苯甲酸衍生物。

  摘要：

  研究了两个系列的降血糖苯甲酸衍生物（5、6）的构效关系。当2-甲氧基被亚烷基亚氨基残基取代时，系列5由美格替宁（3）产生。用顺式3、5-二甲基哌啶子基（5h）和八亚甲基亚氨基（5l）残基观察到最大活性。当将2-甲氧基，5-氟和α-甲基残基替换为2-哌啶子基，5-氢和较大的α-烷基残基时，具有反向酰胺基功能的meglitinide类似物4产生6系列， 分别。羧基邻位的烷氧基残基进一步增加了大鼠的活性和作用时间。最具活性的外消旋化合物6al（R4 =异丁基； R =乙氧基）的活性比磺酰脲（SU）格列本脲（1）高12倍。发现活性主要存在于（S）-对映异构体中。与SUs 1和2（格列美脲）相比，活性最高的对映异构体（S）-6al（AG-EE 623 ZW;瑞格列奈; ED50 = 10 micro / kg po）活性高25和18倍。瑞格列奈对2型糖尿病患者是一种有用的治疗药物。FDA和EMEA最

  DOI：

  10.1021/jm9810349

文献信息

• [EN] SMALL MOLECULE AGONISTS OF MUCOLIPIN 1 AND USES THEREOF<br/>[FR] PETITES MOLÉCULES AGONISTES DE LA MUCOLIPINE 1 ET LEURS UTILISATIONS
  申请人：UNIV MICHIGAN REGENTS

  公开号：WO2021041866A1

  公开（公告）日：2021-03-04

  This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a phenyl-sulfonic amide (or similar) structure which function as agonists of mucolipin 1 (ML1), and their use as therapeutics for the treatment of Duchenne muscular dystrophy (DMD) and related disorders.

  这项发明属于药物化学领域。特别是，该发明涉及一类新的小分子，具有苯磺酰胺（或类似）结构，作为肌球脂蛋白1（ML1）的激动剂，以及它们作为治疗杜氏肌肉萎缩症（DMD）和相关疾病的疗法的用途。
• MONOMERS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME
  申请人：Barany Francis

  公开号：US20140194383A1

  公开（公告）日：2014-07-10

  Described herein are monomers capable of forming a biologically useful multimer when in contact with one, two, three or more other monomers in an aqueous media. In one aspect, such monomers may be capable of binding to another monomer in an aqueous media (e.g. in vivo) to form a multimer, (e.g. a dimer). Contemplated monomers may include a ligand moiety, a linker element, and a connector element that joins the ligand moiety and the linker element. In an aqueous media, such contemplated monomers may join together via each linker element and may thus be capable of modulating one or more biomolecules substantially simultaneously, e.g., modulate two or more binding domains on a protein or on different proteins.

  本发明描述了在水中介质中与一个、两个、三个或更多其他单体接触时能够形成具有生物学用途的多聚体的单体。在一方面，这样的单体可能能够在水介质中（例如，体内）与另一个单体结合形成多聚体（例如，二聚体）。考虑的单体可能包括一个配体部分、一个连接元素和一个连接器元素，连接器元素连接配体部分和连接元素。在水介质中，这样的考虑单体可能通过每个连接元素相互连接，因此可能能够实质上同时调节一个或多个生物分子，例如，调节蛋白质上的两个或多个结合域，或者调节不同蛋白质上的结合域。
• SUBSTITUTED PTERIDINES FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS
  申请人：Herdewijn Piet André Maurits Maria

  公开号：US20090318456A1

  公开（公告）日：2009-12-24

  Tri-substituted pteridines and tetra-substituted pteridines exhibit a significant and selective activity against certain types of viral infections, in particular they selectively inhibit the replication of the hepatitis C virus, and are useful for the prevention and treatment of such infections.

  三取代喹啉和四取代喹啉对某些类型的病毒感染表现出显著和选择性的活性，特别是它们选择性地抑制丙型肝炎病毒的复制，并可用于预防和治疗此类感染。
• [EN] DPP-IV INHIBITORS<br/>[FR] INHIBITEURS DE LA DPP-IV
  申请人：GRAFFINITY PHARMACEUTICALS AG

  公开号：WO2005095343A1

  公开（公告）日：2005-10-13

  The invention relates to compounds of formula (I), Z-C(R<1>R<2>)-C(R<3>NH2)-C(R<4>R<5>)-X-N(R<6>R<7>), wherein Z, R<1-7> and X have the meaning as cited in the description and the claims. Said compounds are useful as DPP-lV inhibitors. The invention also relates to the preparation of such compounds as well as the production and use thereof as medicament.

  该发明涉及式(I)的化合物，其中Z-C(R1R2)-C(R3NH2)-C(R4R5)-X-N(R6R7)，其中Z，R1-7和X的含义如描述和权利要求中所述。所述化合物可用作DPP-IV抑制剂。该发明还涉及制备此类化合物以及其作为药物的生产和使用。
• Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants
  申请人：Zhang Xiaojun

  公开号：US20070003539A1

  公开（公告）日：2007-01-04

  The present invention provides novel phenylglycinamide derivatives of Formula (I) or (IV): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein the variables W, W 1 , Y, Z, R 7 , R 8 , R 9 , and R 11 are as defined herein. These compounds are selective inhibitors of factor VIIa which can be used as medicaments.

  本发明提供了式(I)或(IV)的新型苯基甘氨酰衍生物：或其立体异构体、互变异构体、药学上可接受的盐、溶剂合物或前药，其中变量W、W1、Y、Z、R7、R8、R9和R11如本文所定义。这些化合物是选择性因子VIIa的抑制剂，可用作药物。